StreetAlpha.app
Home › Stocks › UNCY

Unicycive Therapeutics, Inc. (UNCY)

Healthcare
$3.35
▼ −5.10%
LAST CLOSE · NOV 20

Unicycive is a biotechnology company developing drug candidates for kidney disease, including treatments for dialysis patients. It last closed at $3.35 on Nov 20, down 5.10% on the day. The next earnings report for UNCY is expected around Mon, Mar 29, 2027. For the quarter ended Sep 2026, UNCY reported EPS of -$0.25. Over its last 8 reports the stock moved an average of 9.0% the session after earnings.

AI Auto Pilots
Is UNCY in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold UNCY.

Key Stats

Last 12 months
Results
Net income
−$36.2M
EPS (diluted)
−$1.64
Free cash flow
−$29.4M
Valuation
Market cap
$97.8M
29.2M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$42.0M
At Sep 30
Shareholder equity
$52.6M
Shares outstanding
29.2M
At Nov 16
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$10.0M−$10.0MFY2021FY2022: −$18.1M−$18.1MFY2022FY2023: −$30.5M−$30.5MFY2023FY2024: −$36.7M−$36.7MFY2024FY2025: −$26.6M−$26.6MFY2025

From UNCY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · Time not announced
Reported EPS
-$0.25
Quarter ended Sep 2026
Year ago EPS
-$0.33
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$2.64Dec '24Mar 2025: -$0.50Mar '25Jun 2025: -$0.52Jun '25Sep 2025: -$0.33Sep '25Dec 2025: -$0.82Dec '25Mar 2026: -$0.54Mar '26Jun 2026: -$0.06Jun '26Sep 2026: -$0.25Sep '26Latest -$0.25
Revenue by quarter
Not enough quarters on file yet.
How UNCY moved after its last 8 reports
Average move the session after a report ±9.0%
Nov 16, 2026Time not announced+4.2%
Aug 12, 2026Time not announced+7.8%
May 12, 2026Time not announced+2.8%
Mar 30, 2026Time not announced−4.4%
Oct 28, 2025Time not announced−9.9%
Aug 14, 2025Time not announced+5.0%
Jun 30, 2025Time not announced−29.9%
May 14, 2025Time not announced−7.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on UNCYStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on UNCY
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on UNCY

Technical Analysis

UNCY · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 8% below its 20 day and 20% below its 50 day average. It is 75% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 37), near oversold. The nearest support is the 52 week low at $3.33, and the nearest resistance the Pivot at $3.44.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNear oversold
VolatilityNormal, 7.1%/day
Key levels
$8.7452 week high+160.9%
$5.88200 day average+75.5%
$4.66100 day average+39.1%
$4.0350 day average+20.3%
$3.85Swing high (Nov 11)+14.9%
$3.6320 day average+8.4%
$3.53Pivot R1+5.4%
$3.44Pivot+2.7%
$3.35Last close
$3.3352 week low−0.6%
$3.33Swing low (Nov 2)−0.6%
$3.26Pivot S1−2.7%
Indicators
RSI (14)37.37Weak, oversold below 30Neutral
MACD-0.14Above its signal lineBullish
Stochastic26.4Middle of its rangeNeutral
ADX (14)23.0Weak trend
Williams %R-99.0Oversold below −80, overbought above −20Oversold
CCI (20)-161.2Oversold below −100, overbought above 100Oversold
Rate of change−5.6%Change over 10 sessionsBearish
ATR (14)$0.24Typical daily range, 7.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for UNCY

What happened before

See how UNCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow UNCY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How UNCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for UNCYHow many large options trades hit UNCY, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

UNCY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲63 buying vs 29 selling
  • ▼Held by funds -5.7 pts
  • ▲Funds holding +15
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9580+18.8%
In funds' top 1010–
Held by funds39.1%44.8%−5.7 pts
New / increased26 / 3736 / 23+6.8%
Reduced / sold out17 / 1211 / 7+61.1%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See UNCY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether UNCY is in one of them and how their past UNCY trades turned out.

UNCY in the AI portfolios
Loading…

UNCY News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered UNCY in an article yet. Here's the latest on the wider market.

UNCY in the news

About Unicycive Therapeutics

Unicycive is a biotechnology company based in Mountain View, California, that is developing drugs for kidney disease. Its lead candidate, oxylanthanum carbonate, is a tablet meant to control high phosphorus levels in patients on dialysis, and it is designed to be swallowed whole rather than chewed. Its second candidate, UNI-494, is in development for acute kidney injury, a condition for which no FDA approved medicines currently exist. The company plans to seek approvals in the United States and to partner with other drugmakers in other markets.

Headquarters
Mountain View, CA